# Leuko

Source: https://onco.cc/companies/leuko/  
OnCo record `leuko` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leuko is a Massachusetts company developing PointCheck, a fingertip device that checks white blood cell levels without a blood test, so people having chemotherapy can be warned at home when their infection risk is high.

## Summary

Leuko Labs, Inc., an MIT spin-out in Cambridge, Massachusetts, is developing PointCheck, an investigational noninvasive device that shines light into the skin near the fingernail, images blood flow in superficial capillaries and uses AI to assess whether white blood cell levels are dangerously low. The company says it is backed by a Series A round and NIH and NCI SBIR funding. In fiscal year 2026 the National Cancer Institute funded its SBIR project on reducing febrile neutropenia in people treated with chemotherapy with PointCheck (5R44CA228920-06, USD 991,877).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: LEUKO LABS, INC.; Leuko Labs
- HQ: Cambridge, MA
- Type: devices
- Website: https://leuko.com/

## Notes

- Read on leuko.com and the NIH RePORTER record on 4 November 2026. The technology tag is the nearest corpus entry for febrile neutropenia; PointCheck is a monitoring device, not a growth factor.

## Sources

- Official website: https://leuko.com/
- NIH RePORTER: 5R44CA228920-06: https://reporter.nih.gov/project-details/11364218

## Connected records

- fronts: [Devices & Physical Therapies](https://onco.cc/fronts/devices/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Growth factors: G-CSF and febrile neutropenia prevention](https://onco.cc/technologies/g-csf-growth-factors/)
- drugs: [PointCheck](https://onco.cc/drugs/pointcheck/)

---
JSON: https://onco.cc/api/v1/entities/leuko.json